jak1 Antibody

What is JAK1 and why is it an important research target?

JAK1 (Janus kinase 1) is a non-receptor tyrosine kinase central to multiple cytokine signaling pathways, including IFN-alpha/beta/gamma signal transduction. It functions as a kinase partner for several interleukin receptors (IL-2, IL-10) and the type I interferon receptor IFNAR2 . In response to receptor binding, JAK1 phosphorylates and activates IFNAR2, creating docking sites for STAT proteins which enables downstream signaling . JAK1 is expressed at higher levels in primary colon tumors than in normal colon tissue, making it relevant to cancer research . Its importance extends to immune function, hematopoiesis, and cell differentiation, and its dysregulation has been implicated in autoimmune and hematological diseases .

What is the molecular weight of JAK1 protein and what should I expect to see in Western blots?

• Approximately 130 kDa in many standard cell lysates

• 110-120 kDa in NIH-3T3, Daudi, HeLa, and LNCaP cell lines under reducing conditions

• 136 kDa in Daudi cell lysates using Simple Western system

• 139 kDa in Daudi cell lysates using the 12-230 kDa separation system

These variations may reflect post-translational modifications or differences in experimental conditions and detection systems.

Which JAK1 antibody applications are most commonly used in research?

JAK1 antibodies are utilized across multiple research applications, with the following being most common:

The selection of application should be guided by experimental objectives and available validation data for specific antibodies .

Which species reactivity should I consider when selecting a JAK1 antibody?

JAK1 is highly conserved across species, enabling cross-reactivity of many antibodies. When selecting antibodies, consider:

• Human/Mouse/Rat JAK1 antibodies (e.g., MAB4260) demonstrate cross-reactivity across these three species

• Mouse/Rat specific antibodies (e.g., AF602) may offer higher specificity for rodent models

• Species-specific epitopes can be targeted when studying species-specific regulatory mechanisms

• For evolutionary studies, antibodies recognizing conserved domains (e.g., the kinase domain) are preferable

Always validate antibody reactivity in your specific experimental system, especially when working with less common species or when precise species discrimination is required .

How should I optimize JAK1 antibody dilution for Western blot experiments?

Optimizing JAK1 antibody dilution requires systematic testing while considering several variables:

• Starting recommendations:

  • For monoclonal antibodies (e.g., MAB4260), begin with 1 μg/mL

  • For polyclonal antibodies, typically start with 1:1000 dilution

• Optimization protocol:

  • Prepare a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Use consistent lysate amounts from a cell line known to express JAK1 (e.g., Jurkat, K562, HeLa)

  • Process all membranes identically except for primary antibody concentration

  • Select the dilution that gives optimal signal-to-noise ratio

• Cell-type considerations:

  • Higher expression cell lines (e.g., Daudi human Burkitt's lymphoma) may require higher dilutions

  • Lower expression samples may need more concentrated antibody

• Buffer-specific adjustments:

  • Immunoblot Buffer Group 1 has been validated for JAK1 detection in many cells

  • Immunoblot Buffer Group 3 is recommended for Jurkat and K562 cells

Remember that optimal dilutions should be determined by each laboratory for each specific application and sample type .

What controls should be included when using JAK1 antibodies in experimental studies?

Robust experimental design with appropriate controls is critical for JAK1 antibody research:

• Positive controls:

  • Cell lines with confirmed JAK1 expression: Jurkat, K562, Daudi, HeLa, NIH-3T3

  • Recombinant JAK1 protein (when available)

  • JAK1-overexpressing transfected cells

• Negative controls:

  • JAK1 knockout or knockdown samples when possible

  • Secondary antibody only controls to assess non-specific binding

  • Isotype controls matching the primary antibody host species and class

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • Cross-validation with independent antibodies recognizing different epitopes

  • JAK family member controls (JAK2, JAK3, TYK2) to confirm specificity

• Functional controls:

  • Cytokine stimulation (e.g., interferons) to increase JAK1 phosphorylation

  • JAK1 inhibitor treatments (e.g., upadacitinib) to verify signal reduction

These controls help establish specificity, sensitivity, and reliability of results across different experimental conditions .

How can I effectively validate JAK1 antibody specificity for my research application?

Comprehensive validation of JAK1 antibody specificity involves multiple approaches:

• Orthogonal validation:

  • Compare protein detection with mRNA expression data in the same samples

  • Correlate results with genomics data (RNA-seq, microarray) for JAK1

  • Use multiple detection methods (e.g., WB, IHC, and IF) and compare localization

• Genetic validation:

  • Use JAK1 knockout/knockdown models to confirm signal absence

  • For in vivo studies, conditional knockout models (e.g., Jak1fl/fl;Mx1-Cre mouse model) can provide specificity confirmation

  • CRISPR-Cas9 edited cell lines offer precise genetic controls

• Cross-reactivity assessment:

  • Test against recombinant JAK family members (JAK2, JAK3, TYK2)

  • Perform immunoprecipitation followed by mass spectrometry to identify all bound proteins

  • Computational epitope analysis to predict potential cross-reactive proteins

• Independent antibody validation:

  • Use multiple antibodies targeting different epitopes (e.g., MAB4260 targeting Pro32-Phe286 versus antibodies targeting the C-terminal region)

  • Compare monoclonal and polyclonal antibodies to confirm consistent detection patterns

Remember that validation requirements may differ based on application (WB vs. IHC vs. IF) and experimental goals .

What are the optimal tissue and cell preparation methods for JAK1 immunohistochemistry?

Successful JAK1 immunohistochemistry requires careful sample preparation:

• Tissue fixation and processing:

  • For paraffin-embedded sections: 10% neutral buffered formalin fixation for 24-48 hours

  • For frozen sections: Flash freezing in OCT compound followed by cryosectioning

  • Section thickness: 4-6 μm for optimal antibody penetration

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER): Citrate buffer (pH 6.0) at 95-100°C for 20 minutes

  • For human epidermis and similar tissues, immersion fixed paraffin-embedded sections have been validated

  • Some antibodies may require specific buffer conditions (consult product datasheets)

• Blocking and permeabilization:

  • Block with 5-10% normal serum from secondary antibody host species

  • For membrane proteins like JAK1, include 0.1-0.3% Triton X-100 for membrane permeabilization

  • BSA (1-3%) can reduce non-specific binding

• Detection systems:

  • For chromogenic detection: Anti-Rat HRP-DAB Cell & Tissue Staining Kit has been validated for human epidermis

  • For fluorescent detection: NorthernLights™ 557-conjugated secondary antibodies work well for JAK1 visualization in HeLa cells

  • Counterstain with hematoxylin (for chromogenic) or DAPI (for fluorescent) to visualize cellular context

• Incubation parameters:

  • Primary antibody: 10-25 μg/mL concentration at 4°C overnight or room temperature for 1-3 hours

  • Secondary antibody: Follow manufacturer recommendations, typically 1:200-1:1000 for 1 hour at room temperature

These protocols should be optimized for specific tissue types and antibodies used .

What are the common causes of false-positive and false-negative results when using JAK1 antibodies?

Understanding potential sources of error is critical for accurate interpretation:

False-Positive Results:

• Cross-reactivity issues:

  • JAK family homology (JAK1, JAK2, JAK3, TYK2 share structural domains)

  • Non-specific binding to similar epitopes in unrelated proteins

  • Solution: Use highly validated antibodies with demonstrated specificity

• Secondary antibody problems:

  • Excessive concentration leading to non-specific binding

  • Cross-reactivity with endogenous immunoglobulins

  • Solution: Include secondary-only controls and optimize dilutions

• Sample preparation artifacts:

  • Overfixation causing epitope masking or non-specific binding

  • Endogenous peroxidase activity in IHC

  • Solution: Optimize fixation protocols and include appropriate enzyme blocking steps

False-Negative Results:

• Epitope masking:

  • Inadequate antigen retrieval in fixed tissues

  • Post-translational modifications blocking antibody binding sites

  • Solution: Test multiple antigen retrieval methods and use antibodies targeting different epitopes

• Antibody storage and handling:

  • Antibody degradation due to improper storage

  • Repeated freeze-thaw cycles reducing activity

  • Solution: Aliquot antibodies and store according to manufacturer recommendations

• Buffer incompatibility:

  • Incorrect immunoblot buffer groups affecting detection

  • Incompatible reducing/non-reducing conditions

  • Solution: Test different buffer systems (e.g., Immunoblot Buffer Group 1 vs. Group 3)

Systematically evaluating these factors can help troubleshoot problematic results and improve experimental reliability.

How do I interpret varying JAK1 antibody signals across different cell types and tissues?

Variations in JAK1 detection require careful interpretation of biological versus technical factors:

• Biological variation considerations:

  • Cell-type specific expression: JAK1 is expressed at higher levels in primary colon tumors than normal colon tissue

  • Activation state: Cytokine stimulation can alter JAK1 phosphorylation and potentially epitope accessibility

  • Splice variants: JAK1A and JAK1B variants may be differentially detected by some antibodies

  • Post-translational modifications: Phosphorylation and ubiquitination may affect epitope recognition

• Technical variation analysis:

  • Create a standardization curve using recombinant JAK1 protein

  • Normalize to total protein loading rather than single housekeeping proteins

  • Perform quantitative analysis across multiple experiments to establish baseline variability

• Methodological approach to interpreting variations:

  • Compare results across multiple antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression data when possible

  • Consider using multiple detection methods (e.g., both WB and IHC)

  • Validate unusual findings with functional assays (e.g., kinase activity assays)

• Tissue-specific considerations:

  • In human epidermis, JAK1 shows specific localization patterns requiring careful interpretation

  • In hematopoietic tissues, cell subtype heterogeneity must be considered when interpreting whole-tissue signals

  • Cancer tissues may show upregulated expression compared to normal counterparts

What strategies can resolve discrepancies between different JAK1 antibodies in the same samples?

When facing contradictory results from different JAK1 antibodies, systematic investigation is required:

• Epitope mapping analysis:

  • Compare the epitope regions of discrepant antibodies (e.g., MAB4260 targets Pro32-Phe286 region)

  • Antibodies targeting different domains may detect different conformational states or isoforms

  • Post-translational modifications may mask specific epitopes

• Validation hierarchy approach:

  • Prioritize antibodies with enhanced validation documentation

  • Consider independent antibody validation using orthogonal methods

  • Verify with genetic approaches (knockdown/knockout) which antibody shows appropriate specificity

• Technical reconciliation:

  • Optimize conditions for each antibody separately (buffers, dilutions, incubation times)

  • Test both native and denatured detection methods

  • Evaluate performance across multiple applications (WB, IHC, IP) to identify consistent performers

• Quantitative resolution:

  • Implement quantitative Western blotting with standard curves

  • Use JAK1-overexpressing systems as positive controls

  • Apply statistical analysis across multiple experiments to determine reliability

• Result integration approach:

  • When discrepancies persist, report results from multiple antibodies

  • Consider the biological question - some antibodies may be better suited for specific applications

  • Functional validation can help determine which antibody most accurately reflects biologically relevant JAK1

This structured approach helps determine whether discrepancies reflect technical limitations or biologically meaningful differences in JAK1 forms .

How can I distinguish between phosphorylated and unphosphorylated JAK1 in my experiments?

Differentiating JAK1 phosphorylation states requires specific methodological approaches:

• Antibody selection strategy:

  • Use phospho-specific antibodies targeting key phosphorylation sites (Y1034/Y1035 in the activation loop)

  • Compare with total JAK1 antibodies (e.g., MAB4260) that detect both forms

  • Some antibodies may preferentially detect either form despite being marketed as "total" antibodies

• Experimental design considerations:

  • Include positive controls: cytokine-stimulated cells (e.g., interferon treatment) to increase phospho-JAK1

  • Include negative controls: JAK inhibitor-treated samples (e.g., upadacitinib) to reduce phosphorylation

  • Time course experiments to capture transient phosphorylation events

• Technical approaches:

  • Phosphatase treatment of parallel samples to confirm phospho-specificity

  • Immunoprecipitation with total JAK1 antibody followed by immunoblotting with anti-phosphotyrosine antibody (e.g., 4G10)

  • Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated forms based on mobility shift

• Quantification considerations:

  • Always express phospho-JAK1 relative to total JAK1 levels

  • Use digital image analysis with appropriate controls for background subtraction

  • Consider the dynamic range of detection methods when interpreting results

The technical literature indicates that many antibodies like MAB4260 theoretically detect both phosphorylated and unphosphorylated JAK1, but this should be experimentally confirmed for specific research applications .

How are JAK1 antibodies applied in cancer research and what are the key methodological considerations?

JAK1 antibodies serve multiple functions in oncology research, with specific methodological requirements:

• Expression profiling in cancer tissues:

  • JAK1 is expressed at higher levels in primary colon tumors than normal colon tissue

  • IHC protocols have been validated for human epidermis and carcinoma samples

  • Comparison requires careful normalization and matched normal-tumor pairs

  • Multiplex IHC combining JAK1 with tumor markers improves context interpretation

• Signaling pathway analysis:

  • JAK1-STAT3 activation analysis in non-small-cell lung cancer requires careful control selection

  • Parallel assessment of downstream targets (STAT phosphorylation) validates functional status

  • Co-immunoprecipitation studies can reveal cancer-specific JAK1 interactors

  • Inhibitor studies (e.g., upadacitinib) help establish pathway dependencies

• Metastasis and cell migration research:

  • Expression of JAK1 in cancer cells enables individual cells to contract, potentially facilitating metastasis

  • Live cell imaging combined with JAK1 immunofluorescence requires specialized fixation protocols

  • Quantitative analysis must control for cell cycle and density variations

• Therapeutic response prediction:

  • JAK1 inhibition has emerged as a potential treatment strategy for hematological diseases

  • Standardized protocols for JAK1 detection before and after treatment are necessary

  • Patient-derived xenograft models require validated cross-reactive antibodies for translational studies

These applications require careful optimization of protocols and appropriate controls to yield reliable cancer-relevant insights .

What are the latest methodological advances in studying JAK1 using antibody-based approaches in immunology?

Recent innovations have expanded JAK1 antibody applications in immunological research:

• Single-cell resolution techniques:

  • Mass cytometry (CyTOF) using metal-conjugated JAK1 antibodies enables multi-parameter analysis

  • Imaging mass cytometry combines tissue architecture with JAK1 expression at single-cell resolution

  • Flow cytometry protocols for intracellular JAK1 detection in immune cells require specialized permeabilization

• Conditional deletion models for mechanistic studies:

  • Jak1fl/fl;Mx1-Cre mouse models enable temporal control of JAK1 deletion in the hematopoietic system

  • Antibody validation in these models confirms specificity and enables correlation with phenotypes

  • Protocols for detecting residual JAK1 expression following conditional deletion require highly sensitive detection

• Cytokine signaling analysis:

  • JAK1 integrates cytokine sensing to regulate hematopoietic stem cell functions

  • Multiplexed detection of JAK1 with cytokine receptors (IL-2R, IL-10R, IFNAR2) reveals co-localization dynamics

  • Stimulation experiments require precise fixation timing to capture transient interactions

• Advanced imaging applications:

  • Super-resolution microscopy with JAK1 antibodies reveals previously undetectable subcellular localization

  • Live-cell imaging with cell-permeable JAK1 antibody fragments tracks real-time signaling

  • Proximity ligation assays detect JAK1 interactions with binding partners at endogenous expression levels

These methodological advances require careful validation but offer unprecedented insights into JAK1 biology in immune regulation .

How can JAK1 antibodies be applied to study the efficacy and mechanism of JAK inhibitors in preclinical and clinical research?

JAK1 antibodies play crucial roles in development and evaluation of JAK inhibitors:

• Target engagement assessment:

  • In vitro kinase assays combined with immunoprecipitated JAK1 can confirm direct binding

  • Cellular thermal shift assays (CETSA) using JAK1 antibodies detect thermal stabilization upon inhibitor binding

  • Phosphorylation-specific antibodies confirm functional inhibition of JAK1 activity

• Selectivity profiling:

  • Comparative analysis of JAK1 versus JAK2/3/TYK2 inhibition requires selective antibodies

  • Upadacitinib demonstrates ~60-fold selectivity for JAK1 over JAK2 in cellular assays

  • Western blots assessing multiple JAK family members help establish selectivity profiles

• Pharmacodynamic biomarker development:

  • Ex vivo stimulation of clinical samples with cytokines can demonstrate JAK1 inhibition

  • Protocol standardization is critical for reliable quantification across samples

  • Time-course studies reveal duration of target inhibition relative to drug exposure

• Mechanism of action studies:

  • JAK1 antibodies combined with phospho-STAT detection reveal pathway-specific effects

  • Immunophenotyping coupled with JAK1 detection helps explain effects on specific immune cell populations

  • JAK1 detection in animal models of arthritis correlates with efficacy endpoints and reticulocyte deployment

These applications require validated antibodies with demonstrated specificity and quantitative performance characteristics .

What are the methodological considerations when using JAK1 antibodies to study hematopoietic stem cells and differentiation?

JAK1 antibody applications in stem cell research require specialized approaches:

• Hematopoietic stem cell isolation and analysis:

  • JAK1 plays a critical role in HSC maintenance and hematopoietic differentiation

  • Flow cytometry protocols for LT-HSCs (LinˉSca1⁺cKit⁺CD150⁺CD48ˉ) combined with intracellular JAK1 staining require careful optimization

  • Cell sorting followed by Western blot analysis can quantify JAK1 in rare stem cell populations

• Transcriptional regulation analysis:

  • JAK1 deletion leads to downregulation of STAT1/2 and IFN regulatory transcription factors in HSCs

  • Chromatin immunoprecipitation using JAK1 antibodies can identify direct genomic targets

  • Correlation of protein levels with RNA-seq data requires precise quantification protocols

• Differentiation trajectory studies:

  • JAK1 knockout mice show expansion of CD11b⁺GR1⁺ myeloid cells and reduction in B220⁺ lymphocytes

  • Immunophenotyping combined with JAK1 detection tracks changes during differentiation

  • Single-cell protein analysis correlates JAK1 levels with differentiation stages

• Stress response evaluation:

  • JAK1 is important in the response to hematopoietic stress

  • Time-course experiments with synchronized stress induction require standardized protocols

  • Co-detection of stress markers with JAK1 provides mechanistic insights

• Niche interaction studies:

  • Multiplexed immunofluorescence detecting JAK1 along with niche factors

  • In situ detection in bone marrow requires specialized fixation and sectioning methods

  • 3D reconstructions help visualize spatial relationships between JAK1⁺ cells and niche components

These specialized applications benefit from the integration of multiple antibody-based techniques with functional readouts .

JAK1 Antibody Comparison Table for Common Research Applications

Troubleshooting Guide for Common JAK1 Antibody Issues